Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies.

[1]  Steven S. Wong,et al.  An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States , 2021, Hepatology.

[2]  M. Cabana,et al.  Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. , 2020, JAMA.

[3]  S. So,et al.  Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016 , 2020, JAMA network open.

[4]  M. Cabana,et al.  Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. , 2020, JAMA.

[5]  Renee M. Johnson,et al.  Trends in Adolescent Heroin and Injection Drug Use in Nine Urban Centers in the U.S., 1999-2017. , 2019, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[6]  E. Verna,et al.  Opioid epidemic and liver disease , 2019, JHEP reports.

[7]  A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B). , 2018, JAMA.

[8]  J. Singleton,et al.  Vaccination Coverage Among Children Aged 19–35 Months — United States, 2016 , 2017, MMWR. Morbidity and mortality weekly report.

[9]  S. Gordon,et al.  Acute Hepatitis B in an Urban Tertiary Care Hospital in the United States: A Cohort Evaluation , 2013, Journal of clinical gastroenterology.

[10]  R. Janssen,et al.  Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. , 2013, Vaccine.